Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.

Sir Marc Feldmann, Emeritus Professor at the Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences has been awarded the 2020 Tang Prize in Biopharmaceutical Science. He was announced as joint winner alongside Charles Dinarello (US), and Tadamitsu Kishimoto (Japan) "for the development of cytokine-targeting biological therapies for treatment of inflammatory diseases."

Dr Feldmann received the award for his research into the molecular mechanisms of auto-immune inflammatory diseases. This revealed that tumor necrosis factor (TNF), a protein which regulates immune and inflammatory cells was a good therapeutic target in rheumatoid arthritis. This discovery led to the development of an anti-TNF antibody that Feldmann, and his clinical research colleague Maini, proved to be very effective against rheumatoid arthritis and has since enabled millions of patients to regain control of their lives. Anti-TNF was also shown to be effective in inflammatory bowel disease, psoriasis and ten other conditions. It was the first antibody therapy of a common disease, is the world's best-selling drug class, and facilitated the widespread uptake of antibody therapy by the pharmaceutical industry.

The full story is available on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.